Related references
Note: Only part of the references are listed.Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial
Domenica M. Rubino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
Ping Zhong et al.
ENDOCRINE (2022)
Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
Donna H. Ryan
JOURNAL OF OBESITY & METABOLIC SYNDROME (2021)
Heart Disease and Stroke Statistics-2021 Update A Report From the American Heart Association
Salim S. Virani et al.
CIRCULATION (2021)
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial
Thomas A. Wadden et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial
Melanie Davies et al.
LANCET (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
被撤回的出版物: The best drug supplement for obesity treatment: a systematic review and network meta-analysis (Retracted article. See vol. 15, 2023)
Nader Salari et al.
DIABETOLOGY & METABOLIC SYNDROME (2021)
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial
Domenica Rubino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Julie R. Lundgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder
Elvira Anna Carbone et al.
EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY (2021)
Obesity in adults: a clinical practice guideline
Sean Wharton et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2020)
The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity
Minyi Lee et al.
OBESITY SCIENCE & PRACTICE (2020)
Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes
Ronald M. Goldenberg et al.
CANADIAN JOURNAL OF DIABETES (2019)
Projected US State-Level Prevalence of Adult Obesity and Severe Obesity
Zachary J. Ward et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Progress and challenges in anti-obesity pharmacotherapy
Daniel H. Bessesen et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Simulation of Growth Trajectories of Childhood Obesity into Adulthood
Zachary J. Ward et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Sarmad Said et al.
CURRENT VASCULAR PHARMACOLOGY (2016)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
W. Timothy Garvey et al.
ENDOCRINE PRACTICE (2016)
European Guidelines for Obesity Management in Adults
Volkan Yumuk et al.
OBESITY FACTS (2015)
Long-Term Persistence of Hormonal Adaptations to Weight Loss
Priya Sumithran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)